Free Trial

Danaher (DHR) News Today

Danaher logo
$221.13 +12.74 (+6.11%)
Closing price 10/21/2025 03:59 PM Eastern
Extended Trading
$221.21 +0.08 (+0.03%)
As of 05:53 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Why Is Danaher Up Today?

Danaher Corporation (DHR) is trading higher after a better‑than‑expected Q3 showing: the company reported adjusted EPS of $1.89 (above consensus ~$1.71–1.72) and revenue ~ $6.05–6.10B (vs. ~$6.0B). Strength in Diagnostics and Bioprocessing, solid margins and cash generation are being cited as the main drivers of the rally, while FY2025 EPS guidance of $7.70–7.80 came in roughly in line with Street expectations.

  • Positive Sentiment: Q3 beat on both EPS and revenue with Diagnostics and Bioprocessing cited as the growth engines; investors are rewarding the outperformance and resiliency in test/tech demand. Earnings Call Highlights
  • Positive Sentiment: Reporting/coverage highlights Diagnostics unit and life‑sciences tools as the reason for the beat and stronger operating margins, supporting near‑term growth confidence. Reuters: Diagnostics Strength
  • Positive Sentiment: Analyst sentiment remains constructive — J.P. Morgan reiterated a Buy, citing the strong Q3 and strategic investments, which can sustain momentum. TipRanks / J.P. Morgan
  • Neutral Sentiment: FY2025 EPS guidance set at $7.70–7.80 (roughly consensus), so while guidance wasn’t raised meaningfully, it reduced uncertainty by aligning with expectations. PR News Release
  • Neutral Sentiment: Market coverage and screeners are flagging DHR as a top medical/industrial/biotech stock to watch today, increasing visibility but not changing fundamentals. MarketBeat stock lists
  • Negative Sentiment: Rosen Law Firm has opened an investigation into potential breaches of fiduciary duties by Danaher directors/officers—this introduces legal/negativity risk that investors should monitor. Rosen Law Firm investigation

Bottom line for investors: the Q3 beat and segment strength are the primary reasons DHR is trading up; guidance in line and analyst support reinforce the move. Watch legal developments from the Rosen investigation and subsequent management commentary for potential downside volatility.

Posted 10h agoAI Generated. May Contain Errors.

DHR Latest News

Top Medical Stocks To Consider - October 21st
Industrial Stocks To Research - October 21st
Top Biotech Stocks To Research - October 21st
Danaher Corporation (DHR) Q3 2025 Earnings Call Transcript
Danaher’s (NYSE:DHR) Q3 Sales Beat Estimates
Danaher rises as Diagnostics unit powers Q3 beat
Danaher Corporation 2025 Q3 - Results - Earnings Call Presentation
Danaher (NYSE:DHR) Issues FY 2025 Earnings Guidance
Danaher Reports Third Quarter 2025 Results
Examining the Future: Danaher's Earnings Outlook
Eos Management L.P. Lowers Position in Danaher Corporation $DHR
Danaher Earnings: What To Look For From DHR
Promising Biotech Stocks To Research - October 19th
Promising Biotech Stocks To Follow Today - October 18th
Leerink Partnrs Has Pessimistic View of Danaher Q1 Earnings
Get Danaher News Delivered to You Automatically

Sign up to receive the latest news and ratings for DHR and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DHR Media Mentions By Week

DHR Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

DHR
News Sentiment

1.08

0.50

Average
Medical
News Sentiment

DHR News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

DHR Articles
This Week

82

49

DHR Articles
Average Week

Get the Latest News and Ratings for DHR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Danaher and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools


This page (NYSE:DHR) was last updated on 10/22/2025 by MarketBeat.com Staff
From Our Partners